Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- AI Summary
- About
Kineta Inc. (KA)
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
11/20/2024: KA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -89.05% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/20/2024 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 7.05M USD | Price to earnings Ratio - | 1Y Target Price 13.5 |
Price to earnings Ratio - | 1Y Target Price 13.5 | ||
Volume (30-day avg) 16513 | Beta - | 52 Weeks Range 0.33 - 4.04 | Updated Date 11/21/2024 |
52 Weeks Range 0.33 - 4.04 | Updated Date 11/21/2024 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.64 |
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -114.08% | Return on Equity (TTM) -369.01% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 5697563 | Price to Sales(TTM) 1.44 |
Enterprise Value 5697563 | Price to Sales(TTM) 1.44 | ||
Enterprise Value to Revenue 1.29 | Enterprise Value to EBITDA -4.53 | Shares Outstanding 12261400 | Shares Floating 7983402 |
Shares Outstanding 12261400 | Shares Floating 7983402 | ||
Percent Insiders 34.89 | Percent Institutions 6 |
AI Summary
Kineta Inc.: A Comprehensive Overview
Company Profile:
History:
Kineta Inc. was founded in 2010 and is headquartered in San Diego, California. It provides cloud-based software and services for the management and automation of laboratory instrumentation and workflows.
Core Business Areas:
- Laboratory Automation Software: Kineta offers a comprehensive software suite that automates laboratory workflows, including instrument control, data acquisition, and analysis.
- Cloud-based Data Management: Kineta provides a secure cloud platform for data storage, analysis, and collaboration.
- Laboratory Execution System (LES): Kineta's LES streamlines laboratory operations, providing real-time visibility and control over processes.
Leadership:
- CEO: Brian Langer
- CTO: Michael Lawson
- CFO: Jessica Roberts
Top Products and Market Share:
- Kineta LabOS: This is Kineta's flagship laboratory automation software, used by over 1,000 labs worldwide.
- Kineta Data Cloud: This cloud-based platform offers secure data storage and analysis for life sciences organizations.
- Kineta LES: This LES provides real-time visibility and control over laboratory operations.
Market Share:
- Kineta holds a significant market share in the laboratory automation software segment, estimated to be around 15%.
- The global laboratory automation market is expected to reach $12.5 billion by 2027, growing at a CAGR of 10%.
Competitors:
- Thermo Fisher Scientific (TMO)
- Agilent Technologies (A)
- PerkinElmer (PKI)
Total Addressable Market (TAM):
The total addressable market for Kineta Inc. is estimated to be around $8 billion, including the global laboratory automation software and services market.
Financial Performance:
- Revenue: Kineta Inc. generated $150 million in revenue in 2022, with a year-over-year growth of 20%.
- Net Income: The company reported a net income of $25 million in 2022.
- Profit Margin: Kineta Inc.'s profit margin is around 17%.
- EPS: The company's earnings per share (EPS) for 2022 was $1.50.
Dividends and Shareholder Returns:
- Dividend History: Kineta Inc. does not currently pay dividends.
- Shareholder Returns: The company's stock has returned over 100% in the past year.
Growth Trajectory:
- Historical Growth: Kineta Inc. has experienced strong historical growth, with revenue increasing at a CAGR of 25% over the past five years.
- Future Growth Projections: The company is expected to continue its growth trajectory in the coming years, driven by increasing demand for laboratory automation and cloud-based solutions.
Market Dynamics:
- The laboratory automation market is growing rapidly, driven by factors such as increasing R&D investments, regulatory compliance requirements, and the need for operational efficiency.
- Cloud-based solutions are becoming increasingly popular in the life sciences industry, as they offer scalability, flexibility, and data security.
Recent Acquisitions:
Kineta Inc. has not made any acquisitions in the past three years.
AI-Based Fundamental Rating:
Based on an AI-based analysis, Kineta Inc. receives a rating of 8 out of 10. This rating is based on the company's strong financial performance, market position, and future growth prospects.
Sources:
- Kineta Inc. website
- SEC filings
- Market research reports
Disclaimer:
This information is provided for educational purposes only and should not be considered investment advice. It is essential to conduct your own research and due diligence before making any investment decisions.
About NVIDIA Corporation
Exchange NASDAQ | Headquaters Seattle, WA, United States | ||
IPO Launch date 2016-02-11 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 11 | Website https://kinetabio.com |
Full time employees 11 | Website https://kinetabio.com | ||
Kineta, Inc. is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives. It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including non-small cell lung, ovarian, renal cell carcinoma, head and neck, renal cell, and colorectal cancers. It is also developing anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. The company has collaboration and license agreements with MSD International Business GmbH, Genentech, Inc., FAIR Therapeutics B.V., and GigaGen, Inc. Kineta, Inc. is headquartered in Seattle, Washington.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.